array(40) {
  [0]=>
  string(4) "2653"
  ["article_id"]=>
  string(4) "2653"
  [1]=>
  string(59) "Circuit Clinical partners to shape data to drive discovery "
  ["article_title"]=>
  string(59) "Circuit Clinical partners to shape data to drive discovery "
  [2]=>
  string(145) "Circuit Clinical and CUBRC partner to enhance patient data for drug discovery and development services through machine learning platforms and AI."
  ["short_description"]=>
  string(145) "Circuit Clinical and CUBRC partner to enhance patient data for drug discovery and development services through machine learning platforms and AI."
  [3]=>
  string(145) "Circuit Clinical and CUBRC partner to enhance patient data for drug discovery and development services through machine learning platforms and AI."
  ["description"]=>
  string(145) "Circuit Clinical and CUBRC partner to enhance patient data for drug discovery and development services through machine learning platforms and AI."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(164) "https://www.outsourcing-pharma.com/Article/2019/05/14/Circuit-Clinical-partners-to-shape-data-to-drive-discovery?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(164) "https://www.outsourcing-pharma.com/Article/2019/05/14/Circuit-Clinical-partners-to-shape-data-to-drive-discovery?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-14 23:52:00"
  ["add_date"]=>
  string(19) "2019-05-14 23:52:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:24"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2652"
  ["article_id"]=>
  string(4) "2652"
  [1]=>
  string(65) "ACTC selects two drugs for Alzheimer’s for clinical trials"
  ["article_title"]=>
  string(65) "ACTC selects two drugs for Alzheimer’s for clinical trials"
  [2]=>
  string(121) "Japanese pharmaceutical company Eisai sends two new Alzheimerâs prevention drugs into the clinic after ACTC selection."
  ["short_description"]=>
  string(121) "Japanese pharmaceutical company Eisai sends two new Alzheimerâs prevention drugs into the clinic after ACTC selection."
  [3]=>
  string(121) "Japanese pharmaceutical company Eisai sends two new Alzheimerâs prevention drugs into the clinic after ACTC selection."
  ["description"]=>
  string(121) "Japanese pharmaceutical company Eisai sends two new Alzheimerâs prevention drugs into the clinic after ACTC selection."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(156) "https://www.outsourcing-pharma.com/Article/2019/05/14/Two-new-Alzheimer-s-drugs-to-enter-clinical-trials?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(156) "https://www.outsourcing-pharma.com/Article/2019/05/14/Two-new-Alzheimer-s-drugs-to-enter-clinical-trials?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-14 23:44:00"
  ["add_date"]=>
  string(19) "2019-05-14 23:44:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:24"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2654"
  ["article_id"]=>
  string(4) "2654"
  [1]=>
  string(70) "Greenphire partners with Lazarex to ease oncology trial reimbursement "
  ["article_title"]=>
  string(70) "Greenphire partners with Lazarex to ease oncology trial reimbursement "
  [2]=>
  string(148) "Lazarex partners with Greenphire to implement the latterâs ClinCard reimbursement technology to improve patient participation in oncology trials."
  ["short_description"]=>
  string(148) "Lazarex partners with Greenphire to implement the latterâs ClinCard reimbursement technology to improve patient participation in oncology trials."
  [3]=>
  string(148) "Lazarex partners with Greenphire to implement the latterâs ClinCard reimbursement technology to improve patient participation in oncology trials."
  ["description"]=>
  string(148) "Lazarex partners with Greenphire to implement the latterâs ClinCard reimbursement technology to improve patient participation in oncology trials."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(175) "https://www.outsourcing-pharma.com/Article/2019/05/14/Greenphire-partners-with-Lazarex-to-ease-oncology-trial-reimbursement?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(175) "https://www.outsourcing-pharma.com/Article/2019/05/14/Greenphire-partners-with-Lazarex-to-ease-oncology-trial-reimbursement?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-14 23:06:00"
  ["add_date"]=>
  string(19) "2019-05-14 23:06:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:24"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2655"
  ["article_id"]=>
  string(4) "2655"
  [1]=>
  string(54) "PE firm invests in growing eClinical solutions company"
  ["article_title"]=>
  string(54) "PE firm invests in growing eClinical solutions company"
  [2]=>
  string(150) "eClinical technology company, Axiom Real-Time Metrics, will be recapitalized by Great Point Partners to provide eClinical solutions to increase servic"
  ["short_description"]=>
  string(150) "eClinical technology company, Axiom Real-Time Metrics, will be recapitalized by Great Point Partners to provide eClinical solutions to increase servic"
  [3]=>
  string(194) "eClinical technology company, Axiom Real-Time Metrics, will be recapitalized by Great Point Partners to provide eClinical solutions to increase service offerings for Phase I-III clinical trials."
  ["description"]=>
  string(194) "eClinical technology company, Axiom Real-Time Metrics, will be recapitalized by Great Point Partners to provide eClinical solutions to increase service offerings for Phase I-III clinical trials."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(160) "https://www.outsourcing-pharma.com/Article/2019/05/14/PE-firm-invests-in-growing-eClinical-solutions-company?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(160) "https://www.outsourcing-pharma.com/Article/2019/05/14/PE-firm-invests-in-growing-eClinical-solutions-company?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-14 23:01:00"
  ["add_date"]=>
  string(19) "2019-05-14 23:01:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:24"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2793"
  ["article_id"]=>
  string(4) "2793"
  [1]=>
  string(81) "New BIO Report on State of Innovation for Alzheimer’s Disease Therapeutics"
  ["article_title"]=>
  string(81) "New BIO Report on State of Innovation for Alzheimer’s Disease Therapeutics"
  [2]=>
  string(98) "Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases ..."
  ["short_description"]=>
  string(98) "Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases ..."
  [3]=>
  string(843) "Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases ..."
  ["description"]=>
  string(843) "Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases ..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "102"
  ["rss_id"]=>
  string(3) "102"
  [14]=>
  string(130) "http://feedproxy.google.com/~r/BiotechNow/~3/qZ9HX7rgvKs/new-bio-report-on-state-of-innovation-for-alzheimers-disease-therapeutics"
  ["blog_url"]=>
  string(130) "http://feedproxy.google.com/~r/BiotechNow/~3/qZ9HX7rgvKs/new-bio-report-on-state-of-innovation-for-alzheimers-disease-therapeutics"
  [15]=>
  string(19) "2019-05-14 22:33:06"
  ["add_date"]=>
  string(19) "2019-05-14 22:33:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:10"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2800"
  ["article_id"]=>
  string(4) "2800"
  [1]=>
  string(55) "Bayer invests $150m to expand its biologics development"
  ["article_title"]=>
  string(55) "Bayer invests $150m to expand its biologics development"
  [2]=>
  string(150) "Bayer will build a 40,000-square-foot cell culture facility to bolster its capacity to develop therapies primarily focused on oncology and cardiology."
  ["short_description"]=>
  string(150) "Bayer will build a 40,000-square-foot cell culture facility to bolster its capacity to develop therapies primarily focused on oncology and cardiology."
  [3]=>
  string(150) "Bayer will build a 40,000-square-foot cell culture facility to bolster its capacity to develop therapies primarily focused on oncology and cardiology."
  ["description"]=>
  string(150) "Bayer will build a 40,000-square-foot cell culture facility to bolster its capacity to develop therapies primarily focused on oncology and cardiology."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(159) "https://www.biopharma-reporter.com/Article/2019/05/14/Bayer-invests-150m-in-Californian-cell-culture-centre?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(159) "https://www.biopharma-reporter.com/Article/2019/05/14/Bayer-invests-150m-in-Californian-cell-culture-centre?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-14 22:25:00"
  ["add_date"]=>
  string(19) "2019-05-14 22:25:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:13"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:13"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2542"
  ["article_id"]=>
  string(4) "2542"
  [1]=>
  string(115) "CV Sciences’ PlusCBD Oil™ Used in First Study Examining Clinical Benefit of CBD for Patients with PTSD"
  ["article_title"]=>
  string(115) "CV Sciences’ PlusCBD Oil™ Used in First Study Examining Clinical Benefit of CBD for Patients with PTSD"
  [2]=>
  string(74) "Study Finds CBD Associated with PTSD Symptom Reduction in Adults with PTSD"
  ["short_description"]=>
  string(74) "Study Finds CBD Associated with PTSD Symptom Reduction in Adults with PTSD"
  [3]=>
  string(113) "
Study Finds CBD Associated with PTSD Symptom Reduction in Adults with PTSD
"
  ["description"]=>
  string(113) "
Study Finds CBD Associated with PTSD Symptom Reduction in Adults with PTSD
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(171) "http://www.globenewswire.com/news-release/2019/05/14/1823716/0/en/CV-Sciences-PlusCBD-Oil-Used-in-First-Study-Examining-Clinical-Benefit-of-CBD-for-Patients-with-PTSD.html"
  ["blog_url"]=>
  string(171) "http://www.globenewswire.com/news-release/2019/05/14/1823716/0/en/CV-Sciences-PlusCBD-Oil-Used-in-First-Study-Examining-Clinical-Benefit-of-CBD-for-Patients-with-PTSD.html"
  [15]=>
  string(19) "2019-05-14 20:45:00"
  ["add_date"]=>
  string(19) "2019-05-14 20:45:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:54"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2488"
  ["article_id"]=>
  string(4) "2488"
  [1]=>
  string(92) "Pooled Analyses of the Roxadustat Global Phase III Programme Confirmed Cardiovascular Safety"
  ["article_title"]=>
  string(92) "Pooled Analyses of the Roxadustat Global Phase III Programme Confirmed Cardiovascular Safety"
  [2]=>
  string(150) " 10 May 2019 AstraZeneca today announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme f"
  ["short_description"]=>
  string(150) " 10 May 2019 AstraZeneca today announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme f"
  [3]=>
  string(249) " 10 May 2019 AstraZeneca today announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme for roxadustat, a first-in-class hypoxia-inducible-factor prolyl hydroxylase inhibitor (HIF-PHI)...."
  ["description"]=>
  string(249) " 10 May 2019 AstraZeneca today announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme for roxadustat, a first-in-class hypoxia-inducible-factor prolyl hydroxylase inhibitor (HIF-PHI)...."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(270) "https://www.drugs.com/clinical_trials/pooled-analyses-roxadustat-global-phase-iii-programme-confirmed-cardiovascular-safety-18140.html?utm_source=ddc&utm_medium=rss&utm_campaign=Pooled+Analyses+of+the+Roxadustat+Global+Phase+III+Programme+Confirmed+Cardiovascular+Safety"
  ["blog_url"]=>
  string(270) "https://www.drugs.com/clinical_trials/pooled-analyses-roxadustat-global-phase-iii-programme-confirmed-cardiovascular-safety-18140.html?utm_source=ddc&utm_medium=rss&utm_campaign=Pooled+Analyses+of+the+Roxadustat+Global+Phase+III+Programme+Confirmed+Cardiovascular+Safety"
  [15]=>
  string(19) "2019-05-14 14:05:51"
  ["add_date"]=>
  string(19) "2019-05-14 14:05:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:34"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2476"
  ["article_id"]=>
  string(4) "2476"
  [1]=>
  string(67) "Lipocine Announces Tlando NDA PDUFA Action Date of November 9, 2019"
  ["article_title"]=>
  string(67) "Lipocine Announces Tlando NDA PDUFA Action Date of November 9, 2019"
  [2]=>
  string(150) "SALT LAKE CITY, May 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocri"
  ["short_description"]=>
  string(150) "SALT LAKE CITY, May 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocri"
  [3]=>
  string(247) "SALT LAKE CITY, May 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has..."
  ["description"]=>
  string(247) "SALT LAKE CITY, May 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(157) "https://www.drugs.com/nda/tlando_190514.html?utm_source=ddc&utm_medium=rss&utm_campaign=Lipocine+Announces+Tlando+NDA+PDUFA+Action+Date+of+November+9%2C+2019"
  ["blog_url"]=>
  string(157) "https://www.drugs.com/nda/tlando_190514.html?utm_source=ddc&utm_medium=rss&utm_campaign=Lipocine+Announces+Tlando+NDA+PDUFA+Action+Date+of+November+9%2C+2019"
  [15]=>
  string(19) "2019-05-14 12:05:37"
  ["add_date"]=>
  string(19) "2019-05-14 12:05:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4889"
  ["article_id"]=>
  string(4) "4889"
  [1]=>
  string(62) "3rd Annual Bioprocessing and Industrial Biotechnology Congress"
  ["article_title"]=>
  string(62) "3rd Annual Bioprocessing and Industrial Biotechnology Congress"
  [2]=>
  string(150) "3rd Annual Bioprocessing and Industrial Biotechnology Congress commences from October 14-15, 2019 at one of the most attractive city of the world, Bru"
  ["short_description"]=>
  string(150) "3rd Annual Bioprocessing and Industrial Biotechnology Congress commences from October 14-15, 2019 at one of the most attractive city of the world, Bru"
  [3]=>
  string(503) "3rd Annual Bioprocessing and Industrial Biotechnology Congress commences from October 14-15, 2019 at one of the most attractive city of the world, Brussels, Belgium.&#nlBioprocess 2019 aims to bring together the professors, researchers, scientists, business giants, and technocrats to provide an international forum for the dissemination of original research results, new ideas and practical development and discover advances in the field of biotechnology, management and education in relation to bio..."
  ["description"]=>
  string(503) "3rd Annual Bioprocessing and Industrial Biotechnology Congress commences from October 14-15, 2019 at one of the most attractive city of the world, Brussels, Belgium.&#nlBioprocess 2019 aims to bring together the professors, researchers, scientists, business giants, and technocrats to provide an international forum for the dissemination of original research results, new ideas and practical development and discover advances in the field of biotechnology, management and education in relation to bio..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(94) "https://www.pharmiweb.com/event/3rd-annual-bioprocessing-and-industrial-biotechnology-congress"
  ["blog_url"]=>
  string(94) "https://www.pharmiweb.com/event/3rd-annual-bioprocessing-and-industrial-biotechnology-congress"
  [15]=>
  string(19) "2019-05-14 10:19:42"
  ["add_date"]=>
  string(19) "2019-05-14 10:19:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:12:08"
  ["create_at"]=>
  string(19) "2019-09-27 14:12:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2489"
  ["article_id"]=>
  string(4) "2489"
  [1]=>
  string(155) "Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids"
  ["article_title"]=>
  string(155) "Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids"
  [2]=>
  string(150) "BASEL, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and comm"
  ["short_description"]=>
  string(150) "BASEL, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and comm"
  [3]=>
  string(252) "BASEL, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that..."
  ["description"]=>
  string(252) "BASEL, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/myovant-sciences-announces-positive-phase-3-results-liberty-1-study-evaluating-once-daily-relugolix-18146.html?utm_source=ddc&utm_medium=rss&utm_campaign=Myovant+Sciences+Announces+Positive+Phase+3+Results+from+LIBERTY+1+Study+Evaluating+Once+Daily+Relugolix+Com"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/myovant-sciences-announces-positive-phase-3-results-liberty-1-study-evaluating-once-daily-relugolix-18146.html?utm_source=ddc&utm_medium=rss&utm_campaign=Myovant+Sciences+Announces+Positive+Phase+3+Results+from+LIBERTY+1+Study+Evaluating+Once+Daily+Relugolix+Com"
  [15]=>
  string(19) "2019-05-14 09:05:51"
  ["add_date"]=>
  string(19) "2019-05-14 09:05:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:34"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2471"
  ["article_id"]=>
  string(4) "2471"
  [1]=>
  string(116) " FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma"
  ["article_title"]=>
  string(116) " FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma"
  [2]=>
  string(150) "Darmstadt, Germany and New York, US, May 14, 2019 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono "
  ["short_description"]=>
  string(150) "Darmstadt, Germany and New York, US, May 14, 2019 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono "
  [3]=>
  string(244) "Darmstadt, Germany and New York, US, May 14, 2019 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug..."
  ["description"]=>
  string(244) "Darmstadt, Germany and New York, US, May 14, 2019 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-bavencio-avelumab-plus-inlyta-axitinib-combination-patients-advanced-renal-cell-4973.html?utm_source=ddc&utm_medium=rss&utm_campaign=+FDA+Approves+Bavencio+%28avelumab%29+Plus+Inlyta+%28axitinib%29+Combination+for+Patients+with+Advanced+Renal+Cell+Carcinom"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-bavencio-avelumab-plus-inlyta-axitinib-combination-patients-advanced-renal-cell-4973.html?utm_source=ddc&utm_medium=rss&utm_campaign=+FDA+Approves+Bavencio+%28avelumab%29+Plus+Inlyta+%28axitinib%29+Combination+for+Patients+with+Advanced+Renal+Cell+Carcinom"
  [15]=>
  string(19) "2019-05-14 08:05:06"
  ["add_date"]=>
  string(19) "2019-05-14 08:05:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:26"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:26"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}